J. Bloss - Concepedia

Author

J. Bloss

University of Iowa

Also Known As

J D Bloss, J. Bloss, J. D. Bloss, J.D. Bloss, Jeffery Bloss, Jeffery D. Bloss, Jennifer R. Bloss

Publications

561

Citations

H-Index

Concepts

All Affiliations

University of Iowa

About

J. Bloss is an author at University of Iowa specializing in medicine, oncology, and obstetrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	242
2	Obstetrics	3	3	139
3	Pharmacology	3	3	145
4	Pathology	1	1	35
5	Surgical Oncology	1	1	23

J. Bloss

Publications

242

Citations

H-Index

Page 1

	Year	Citations
A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer D. Scott McMeekin, Alan N. Gordon, Jeffrey M. Fowler, Gynecologic Oncology Advanced Endometrial CancerOncologyPhase Ii TrialMedicineGynecology	2003	81
A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) non-small cell lung cancer (NSCLC): Update of the Alpha Oncology trial (A1–99002L) Joseph Treat, Chandra P. Belani, Martin J. Edelman, Journal of Clinical Oncology Advanced NsclcTherapeutic Drug MonitoringOncologyMedicineMetronomic Therapy	2005	53
Ophthalmomyiasis interna anterior associated with Cuterebra spp in a cat P. Elliott Miller, J. Bloss, Phillip Pellitteri Journal of the American Veterinary Medical Association Ocular DiseaseOphthalmologyExperimental OphthalmologyPathogenesisVeterinary Science	2000	39
Serum CA125 regression in epithelial ovarian cancer: Correlation with reassessment findings and survival Richard E. Buller, Michael L. Berman, J. Bloss, Gynecologic Oncology Epithelial Ovarian CancerMedicinePathologyGynecologySerum Ca125 Regression	1992	35
Extraovarian peritoneal serous papillary carcinoma: A case‐control retrospective comparison to papillary adenocarcinoma of the ovary J. Bloss, S Y Liao, R.E. Buller, International Journal of Gynecology & Obstetrics Surgical OncologyTumoral PathologyGynecological SurgerySurgical PathologyGynecology	1994	23
53 POSTER A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer Roy S. Herbst, Vince O’Neill, Louis Fehrenbacher, European Journal of Cancer Supplements MedicinePharmacologyClinical TrialsErlotinib HydrochlorideImmune Checkpoint Inhibitor	2006	11

Page 1